Is Sermorelin Legal in Maryland?

What Sermorelin Is and Why Its Legal History Matters

Sermorelin acetate is a 29-amino-acid analog of endogenous growth hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors and stimulates the pulsatile release of endogenous growth hormone rather than supplying exogenous GH directly. Published pharmacodynamic data confirm dose-dependent GH and IGF-1 elevation in both pediatric and adult populations.

The NDA Withdrawal of 2008

Serono held FDA approval for Geref (sermorelin acetate) for injectable use in pediatric GH deficiency. Serono withdrew the NDA voluntarily in 2008 for commercial reasons, not safety concerns. The FDA's withdrawal summary makes clear that no safety signal triggered the decision. Once a drug's NDA is withdrawn, it cannot be sold as a finished pharmaceutical product, but it does not disappear from medicine entirely. Compounding pharmacies operating under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act may still prepare it from bulk active pharmaceutical ingredient (API) provided the ingredient is not on FDA's list of bulk substances that may not be used in compounding.

DEA and Controlled Substance Status

Sermorelin does not appear on any DEA schedule. The DEA list of controlled substances (Schedules I through V) covers opioids, stimulants, benzodiazepines, anabolic steroids, and certain peptides such as GHRP-6 and GHRP-2 when classified as anabolic agents, but sermorelin itself has not been scheduled. A prescriber in Maryland therefore does not need a DEA COR to prescribe it, and patients do not face the dispensing restrictions that apply to Schedule III or IV drugs.

Federal Compounding Law: The 503A and 503B Framework

Understanding whether a compounding pharmacy can legally prepare sermorelin requires understanding two distinct federal pathways. Both are administered by the FDA's Center for Drug Evaluation and Research (CDER).

Section 503A: Traditional Compounding Pharmacies

Under 21 U.S.C. § 353a, a 503A pharmacy may compound a drug for an identified individual patient based on a valid prescription. The compounded product must not be a copy of a commercially available drug, must use bulk ingredients that appear on FDA's 503A bulks list or are otherwise permitted, and must comply with USP sterile compounding standards (USP <797>). USP <797> was substantially revised in 2023, tightening beyond-use dating and environmental monitoring requirements for sterile preparations like sermorelin.

Sermorelin is a sterile injectable peptide. Any 503A pharmacy compounding it must maintain a cleanroom environment, validated beyond-use dates, and documented sterility testing. Patients in Maryland receiving sermorelin from a 503A pharmacy should verify that the pharmacy holds a current state board license and that it has passed an FDA inspection without an active warning letter.

Section 503B: Outsourcing Facilities

A 503B outsourcing facility may produce larger batches without patient-specific prescriptions and may ship across state lines. These facilities are subject to current good manufacturing practice (cGMP) standards, making them structurally closer to conventional drug manufacturers. The FDA publishes a searchable list of registered 503B outsourcing facilities; Maryland patients and prescribers can confirm that a given outsourcing facility appears on that list before ordering.

The Bulks List Question

FDA maintains two key lists for compounding: a "positive list" of bulk substances that 503A pharmacies may use, and a parallel process for 503B. As of early 2025, sermorelin is not on FDA's list of bulk drug substances that may not be used in compounding. It also does not appear on the 503B bulks list of prohibited substances. That means sermorelin occupies a permissible compounding category, though FDA retains authority to revisit this classification. Prescribers and patients should confirm current status at the time of any new prescription by checking the FDA's compounding pages directly.

Maryland State Law: No Additional Sermorelin-Specific Restrictions

Maryland does not have a statute or regulation that singles out sermorelin for special restriction beyond federal requirements. The governing state-level authority is the Maryland Board of Pharmacy, which licenses pharmacies and enforces COMAR Title 10, Subtitle 34 for compounding practice. Those regulations mirror USP <797> for sterile preparations and require that compounding pharmacies hold a current Maryland non-resident or in-state pharmacy permit.

Maryland Medical Practice Act

Prescribing sermorelin in Maryland requires compliance with the Maryland Medical Practice Act (Md. Code Ann., Health Occ. §§ 14-101 et seq.) and its equivalent statutes for nurse practitioners and physician assistants. A clinician must establish a valid patient-provider relationship, document a clinical indication, and write a prescription that meets Maryland's standard of care. Off-label prescribing of a compounded drug is permitted under Maryland law, consistent with the AMA's position on off-label prescribing, provided the clinician documents the medical rationale.

Telehealth Prescribing in Maryland

Maryland's telehealth parity law requires insurers to cover telehealth services on par with in-person visits and does not prohibit telehealth prescribing of non-controlled compounded drugs. A Maryland-licensed provider conducting a synchronous audio-video visit with a Maryland patient may legally prescribe sermorelin. The prescription must still be routed to a licensed pharmacy, and the provider must maintain appropriate documentation as required by the Board of Physicians under COMAR 10.32.

Clinical Evidence Supporting Sermorelin Use

Legal permissibility does not by itself justify prescribing. A brief review of the clinical evidence helps clinicians and patients understand why sermorelin continues to be ordered despite the NDA withdrawal.

Growth Hormone Secretion and IGF-1 Response

A double-blind crossover study published in the Journal of Clinical Endocrinology and Metabolism demonstrated that sermorelin 0.2 mg/day subcutaneously for 6 months increased mean IGF-1 by approximately 30% in older men with low-normal GH secretion. A separate analysis in the same cohort showed measurable improvements in lean body mass and reductions in fat mass, though effect sizes were modest compared with recombinant human GH (rhGH).

Comparison With Exogenous rhGH

The Endocrine Society's 2019 clinical practice guideline on growth hormone deficiency in adults recommends rhGH as the standard treatment for confirmed adult GHD. Sermorelin is not mentioned as a first-line agent in that guideline because it lacks the same evidentiary base. Clinicians who prescribe sermorelin for adult GHD typically do so for patients who prefer a secretagogue approach, who experience IGF-1 overshoot with rhGH, or who are seeking a lower-cost alternative. The 2019 Endocrine Society guideline explicitly states: "In adults with GHD, GH therapy improves body composition, exercise capacity, skeletal integrity, and quality of life."

Safety Profile

The adverse-effect profile of sermorelin is generally mild. FDA adverse event data and published literature identify injection-site reactions, transient facial flushing, and headache as the most common events. Because sermorelin stimulates endogenous GH rather than bypassing pituitary regulation, the risk of GH-induced insulin resistance and edema appears lower than with supraphysiologic rhGH doses. A 2020 review in Frontiers in Endocrinology summarized the safety data available for GHRH analogs and found no signals for malignancy promotion at therapeutic doses, though long-term data beyond 24 months remain limited.

IGF-1 Monitoring

The Endocrine Society recommends maintaining IGF-1 within the age- and sex-adjusted normal range during any GH-axis therapy. For sermorelin, most clinicians check a baseline IGF-1, recheck at 8 to 12 weeks after starting therapy, and titrate dose accordingly. Serum IGF-1 above the upper limit of normal warrants dose reduction or temporary discontinuation. This monitoring protocol does not differ materially from rhGH monitoring and is well-supported by published Endocrine Society standards.

How to Get Sermorelin Legally in Maryland

The pathway below reflects the current regulatory environment as of early 2025. It is the framework the HealthRX medical team uses when evaluating patients in Maryland for sermorelin therapy.

Step 1: Establish Clinical Indication

A clinician must document why sermorelin is being considered. Accepted indications include confirmed or suspected adult growth hormone deficiency, functional GH decline associated with aging and supported by low IGF-1, and recovery support in specific patient populations where the prescribing clinician can document medical necessity. A basal IGF-1 below the age-adjusted reference interval is the most common objective trigger.

Step 2: Choose a Qualified Prescriber

The prescriber must hold a current Maryland license (or be licensed in the state where the telehealth patient physically sits at the time of the visit). Relevant Maryland boards include the Board of Physicians for MDs and DOs, and equivalent boards for advanced practice clinicians. The prescriber should document the patient-provider relationship, the clinical rationale, and any prior treatments attempted.

Step 3: Use an FDA-Registered Compounding Pharmacy

The prescription must go to either a Maryland-licensed 503A compounding pharmacy or an FDA-registered 503B outsourcing facility. The FDA's 503B facility list is updated regularly. Patients should ask their pharmacy for its current PCAB accreditation status and request a certificate of analysis (COA) for each dispensed lot. A COA from an ISO-accredited third-party lab confirms potency, sterility, and endotoxin levels.

Step 4: Confirm No Active FDA Warning Letter

The FDA's warning letter database is publicly searchable. Before filling a sermorelin prescription, patients and providers should confirm that the chosen compounding pharmacy has not received an active warning letter citing sterility failures or adulterated peptide products. Several compounders received such letters between 2020 and 2024 related to inadequate sterility testing.

Step 5: Ongoing Monitoring

After dispensing, a compliant sermorelin program includes IGF-1 measurement at baseline and at 8 to 12 weeks, periodic blood glucose monitoring (given GH's counter-regulatory effects on insulin), and documentation of clinical response. The American Association of Clinical Endocrinologists recommends annual re-evaluation of continued need for GH-axis therapy in adults.

What Makes a Sermorelin Prescription Invalid in Maryland

Not all sermorelin prescriptions are legally defensible. The following scenarios create legal or regulatory exposure for both the prescriber and the patient.

A prescription written without a clinical encounter or without documented medical necessity may constitute unprofessional conduct under Md. Code Ann., Health Occ. § 14-404. Filling a prescription at a pharmacy that is not licensed in Maryland and is not a registered 503B outsourcing facility means the patient receives a drug dispensed outside lawful channels. Purchasing sermorelin from a research-chemical vendor without a prescription, which some internet suppliers support, violates the FD&C Act's prescription drug provisions at 21 U.S.C. § 353 and exposes the buyer to unapproved, untested product.

The phrase "research use only" on a supplier's label does not create a legal exemption for human use. FDA has sent multiple warning letters to vendors marketing peptides labeled for research use when the products are clearly intended for human consumption.

Maryland-Specific Regulatory Resources

Patients and providers can verify current status using these primary sources directly.

The Maryland Board of Pharmacy maintains a public license lookup for all pharmacies permitted to operate in the state. The Maryland Board of Physicians similarly offers a license verification tool. The FDA's Drug Shortages and Compounding page documents any new additions to prohibited bulks lists as they occur. Checking these sources at the time of prescription is good practice, not optional diligence.

Frequently Asked Questions